|
GB202101656D0
|
|
Engineered transposase and uses thereof
|
|
GB202019108D0
|
|
Vector
|
|
GB202018657D0
|
|
Agents and methods for increasing liver immune response
|
|
WO2020239964A1
|
|
Agents and methods for treating viral infections
|
|
WO2020208206A1
|
|
Method for analysing insertion sites
|
|
WO2020201326A1
|
|
Aminoguanidine hydrazones as retromer stabilizers useful for treating neurological diseases
|
|
WO2020152367A1
|
|
Inhibitor of dux4 and uses thereof
|
|
WO2020148401A1
|
|
Biomarkers for renal cell carcinoma
|
|
WO2020109620A2
|
|
Bacterial strains for medical uses
|
|
WO2020074729A1
|
|
Selection by means of artificial transactivators
|
|
WO2020070089A1
|
|
Chromogranin a and uses thereof
|
|
WO2020053395A1
|
|
Method for determining artificial pump dysfunction
|
|
WO2020049069A1
|
|
Asparagine synthetase inhibitors and uses thereof
|
|
CA3110098A1
|
|
Tricyclic inhibitors of hepatitis b virus
|
|
AU2019312500A1
|
|
Combination of a glycosylation inhibitor with one car cell therapy for treating cancer
|
|
WO2020016434A1
|
|
Cyclic inhibitors of hepatitis b virus
|
|
CA3106839A1
|
|
Inhibitors of hepatitis b virus
|
|
KR20210030941A
|
|
Gene therapy
|
|
GB201905301D0
|
|
Gene therapy
|
|
WO2019170845A1
|
|
Il-1 antagonist and toxicity induced by cell therapy
|
